0000914475-24-000056.txt : 20240214
0000914475-24-000056.hdr.sgml : 20240214
20240214171701
ACCESSION NUMBER: 0000914475-24-000056
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240213
FILED AS OF DATE: 20240214
DATE AS OF CHANGE: 20240214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GORMAN KEVIN CHARLES
CENTRAL INDEX KEY: 0001201096
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 24640584
MAIL ADDRESS:
STREET 1: 12790 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 330525145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
wk-form4_1707948998.xml
FORM 4
X0508
4
2024-02-13
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001201096
GORMAN KEVIN CHARLES
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
1
1
0
0
Chief Executive Officer
0
Common Stock
2024-02-13
4
M
0
2778
35.99
A
509740
D
Common Stock
2024-02-13
4
M
0
2312
43.24
A
512052
D
Incentive Stock Option
35.99
2024-02-13
4
M
0
2778
35.99
D
2026-02-05
Common Stock
2778
0
D
Incentive Stock Option
43.24
2024-02-13
4
M
0
2312
43.24
D
2027-02-06
Common Stock
2312
0
D
This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock.
491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.
The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning March 5, 2016.
The option was granted February 6, 2017 and vested in 48 equal monthly installments beginning March 6, 2017.
/s/ Darin Lippoldt, Attorney-in-Fact
2024-02-14